Literature DB >> 10537059

Transport of cationized anti-tetanus Fab'2 fragments across an in vitro blood-brain barrier model: involvement of the transcytosis pathway.

J Girod1, L Fenart, A Régina, M P Dehouck, G Hong, J M Scherrmann, R Cecchelli, F Roux.   

Abstract

Tetanus neurotoxin reaches the CNS by axonal retrograde transport and thus becomes inaccessible to current treatments. A possible strategy to improve current therapy for tetanus disease would be the vectorization of Fab'2 fragments, allowing their delivery into the CNS. The purpose of this study was to investigate whether after cationization anti-tetanus Fab'2 fragments are able to cross the blood-brain barrier, the first obstacle to CNS delivery. We used primary cocultures of bovine brain capillary endothelial cells and newborn rat astrocytes as an in vitro model to study the binding and transport of cationized Fab'2 (cFab'2) fragments across the brain endothelium. We first show that cationization does not alter Fab'2 affinity for tetanus toxin. Then we demonstrate that after cationization Fab'2 fragments are able to bind to the negative charges on the surface of endothelial cells and subsequently to be transported across the endothelial cell monolayer without any modification of affinity. Finally, using fluorescence microscopy, we show that cFab'2 fragments are transported through endocytotic vesicles. The present study demonstrates that cationization allows Fab'2 directed against tetanus toxin to be transported through brain endothelium by adsorptive-mediated transcytosis. We suggest that this vectorization way could be a promising delivery strategy for carrying anti-tetanic immunoglobulin fragments across the blood-brain barrier to improve tetanus treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10537059

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  6 in total

1.  Inhibition of cocaine binding to the human dopamine transporter by a single chain anti-idiotypic antibody: its cloning, expression, and functional properties.

Authors:  Mitchell Ho; Mariangela Segre
Journal:  Biochim Biophys Acta       Date:  2003-07-30

Review 2.  Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology.

Authors:  Máiria A Deli; Csongor S Abrahám; Yasufumi Kataoka; Masami Niwa
Journal:  Cell Mol Neurobiol       Date:  2005-02       Impact factor: 5.046

Review 3.  CNS delivery via adsorptive transcytosis.

Authors:  Françoise Hervé; Nicolae Ghinea; Jean-Michel Scherrmann
Journal:  AAPS J       Date:  2008-08-26       Impact factor: 4.009

Review 4.  Surface charge, glycocalyx, and blood-brain barrier function.

Authors:  Fruzsina R Walter; Ana R Santa-Maria; Mária Mészáros; Szilvia Veszelka; András Dér; Mária A Deli
Journal:  Tissue Barriers       Date:  2021-05-18

Review 5.  Non-Invasive Delivery of Therapeutics into the Brain: The Potential of Aptamers for Targeted Delivery.

Authors:  Bakhtiar Bukari; Rasika M Samarasinghe; Jinjutha Noibanchong; Sarah L Shigdar
Journal:  Biomedicines       Date:  2020-05-14

6.  Human Recombinant Fab Fragment Neutralizes Shiga Toxin Type 2 Cytotoxic Effects in vitro and in vivo.

Authors:  Daniela Luz; Maria Marta Amaral; Flavia Sacerdoti; Alan Mauro Bernal; Wagner Quintilio; Ana Maria Moro; Marina Sandra Palermo; Cristina Ibarra; Roxane Maria Fontes Piazza
Journal:  Toxins (Basel)       Date:  2018-12-02       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.